Patient Considerations in R/R Mantle Cell Lymphoma Treatment: Anita Kumar, MD

Video

The Regional Care Network Medical Site Director at Memorial Sloan Kettering Cancer Center Basking Ridge discussed patient factors to consider when selecting treatment in R/R MCL.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, about patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma (MCL).

Kumar discussed several patient considerations that should be accounted for at the time of treatment initiation, including age, overall fitness, and existing comorbidities. Patient goals with therapies should also be considered, Kumar added. Some patients prefer to receive well-tolerated therapies to maximize quality of life, whereas others prefer to treat their MCL aggressively with all available options, Kumar said. Moreover, patient preference could determine whether they should be treated in a community setting vs an academic setting, Kumar added.

Other considerations include whether the patient is eligible for CAR T-cell therapy, autologous stem cell transplant, and allogeneic stem cell transplant, Kumar says. Regarding the latter, donor availability then becomes an additional factor to consider, Kumar concluded.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.